# Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

> **NCT02526017** · PHASE1 · COMPLETED · sponsor: **Five Prime Therapeutics, Inc.** · enrollment: 313 (actual)

## Conditions studied

- Advanced Solid Tumors
- Head and Neck Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Malignant Glioma
- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Cabiralizumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02526017
- **Lead sponsor:** Five Prime Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-08
- **Primary completion:** 2019-11-18
- **Final completion:** 2019-11-18
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2022-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02526017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02526017, "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02526017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*